A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES

One hundred and twelve patients received hematopoietic stent cell transplantation (HSCT), including 91patients with acute leukemia, 12 patients with chronic nyeloid leukemia, 7 patients with lymphoma and 2patients with myeloma and neuroblastoma respectively.Among them, 14 patients were treated with unpurged autologous bone marrow transplantation (ABMT), 25patients with purged autologous bone marrow transplantation (PABMT), 40 patients with autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT), 24 patients with allogencic bone marrow transplautation (Allo-BAT), 9 patients with fetal liver hematopoietic stem cell transplantation (FLHSCT). The three year disease free survival (DFS) rates in these five groups were 68.3%, 67.5%, 69.54%, 57.12% and 33.33%respectively. The relapse rates were 30.76%, 26.80%,20.8%, 13% and 62.5% respectively. In contrast, in the conventional chemotherapy group, the three year DFS rate and relapse rate were 7.385 and 76.4% respectively.These results indicated that the APBHSCT group had a quicker hematopoietic reconstitution with less complication of infection. All of these five transplantation groups had much higher three years disease free survival rates than that of the conventional chemotherapy group.

造血干细胞移植治疗白血病及其他恶性肿瘤112例临床研究

报告造血干细胞移植治疗白血病及其他恶性肿瘤１１２例，其中急性白血病９１例，慢性粒细胞白血病１２例，恶性淋巴瘤７例，骨随瘤及神经母细胞瘤各１例。１１２例中自体骨髓移植（ＡＢＭＴ）１４例，净化自体骨髓移植（ＰＡＢＭＴ）２５例，自体外周血干细胞移植（ＡＢＨＳＣＴ）４０例，异基固骨髓移植（Ａｌｌｏ－ＢＭＴ）２４例，胎肝造血干细胞移植（ＦＬＨＳＣＴ）９例，３年无病生存率（ＤＦＳ）及复发率分别为６８．３２％、６７．５７％、６９．５４％、５７．１２％、３３．３３％和３０．７６％、２６．８０％、２０．０８％、１３．００％、６２．５０％。同期化疗患者３年ＤＦＳ率及复发率分别为７．３８％及７６．４％。五个移植组疗效明显优于化疗组。